Sessions:
- US Session: Tuesday, July 15 | 10:00 AM ET
- APAC Session: Tuesday, July 21 | 10:00 AM JST (Monday, July 20, 9 PM US ET)
Services: 定量系统药理学咨询
产品： Certara IQ™
Getting started with using mechanistic modeling to guide portfolio decisions
How do you know if a drug will work, before you even make the molecule?
At the earliest stages of discovery, teams are making critical decisions about targets, modalities, and design strategies with limited data. Mechanistic modeling offers a powerful way to evaluate feasibility, define optimal drug properties, and prioritize the most promising paths forward, before significant resources are committed.
Join Certara experts Marc Presler, PhD, and Sarah DiBartolo, PhD, for a live Q&A-style webinar focused on applying early-stage biosimulation to biologics discovery. This session is designed to give you access to experts in this area to help answer your questions on how modeling can support faster, more confident portfolio decisions early in drug discovery.
What you’ll learn
- What “early feasibility” means and why it matters in biologics discovery
- How mechanistic modeling can inform target selection and candidate prioritization
- How to define optimal drug properties (e.g., affinity, half-life, valency) before molecule generation
- What inputs and data are needed to get started with early-stage modeling
- How to apply biosimulation to triage non-viable concepts and focus resources
点击报名
Marc Presler, PhD
Director, QSPMeet Marc Presler, a member of Certara QSP’s Team! Marc has leveraged deep expertise in fundamental biology and quantitation to support over 70 drug programs. He sees models as powerful tools that help integrate evidence to improve decision-making in drug development.
His contributions have ranged from clinical trial design, first-in-human dose projections, to initial concept design, working with collaborators spanning large pharma to pre-seed biotechs.
Marc is particularly excited about bringing biosimulation insights into the earliest stages of drug discovery. He is currently working on developing the “industrial” capabilities that will allow the analysis of discovery pipelines at scale:
What if biosimulation were used to ensure favorable pharmacology for every new drug concept at the beginning of a program?
Sarah DiBartolo
Sr Scientist, QSP ConsultancyWith 10+ years experience, Sarah’s expertise in QSP modeling spans the entire drug development pipeline, from early feasibility assessment to clinical and post-market analyses, with a focus on Alzheimer’s Disease.
点击报名
